JP2015508092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508092A5 JP2015508092A5 JP2014558118A JP2014558118A JP2015508092A5 JP 2015508092 A5 JP2015508092 A5 JP 2015508092A5 JP 2014558118 A JP2014558118 A JP 2014558118A JP 2014558118 A JP2014558118 A JP 2014558118A JP 2015508092 A5 JP2015508092 A5 JP 2015508092A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- compound according
- alkyl group
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 208000011661 metabolic syndrome X Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382066.4 | 2012-02-24 | ||
| EP12382066 | 2012-02-24 | ||
| PCT/EP2013/053554 WO2013124413A1 (en) | 2012-02-24 | 2013-02-22 | Thiadiazolidinediones as gsk-3 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000211A Division JP6518270B2 (ja) | 2012-02-24 | 2017-01-04 | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508092A JP2015508092A (ja) | 2015-03-16 |
| JP2015508092A5 true JP2015508092A5 (2) | 2015-10-15 |
| JP6073377B2 JP6073377B2 (ja) | 2017-02-01 |
Family
ID=47747639
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558118A Active JP6073377B2 (ja) | 2012-02-24 | 2013-02-22 | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
| JP2017000211A Active JP6518270B2 (ja) | 2012-02-24 | 2017-01-04 | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000211A Active JP6518270B2 (ja) | 2012-02-24 | 2017-01-04 | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9371299B2 (2) |
| EP (1) | EP2838888B1 (2) |
| JP (2) | JP6073377B2 (2) |
| AU (2) | AU2013224041B2 (2) |
| CA (1) | CA2865351C (2) |
| CY (1) | CY1119231T1 (2) |
| DK (1) | DK2838888T3 (2) |
| ES (1) | ES2632428T3 (2) |
| HR (1) | HRP20170964T1 (2) |
| HU (1) | HUE035089T2 (2) |
| IN (1) | IN2014DN07885A (2) |
| LT (1) | LT2838888T (2) |
| NZ (1) | NZ630615A (2) |
| PL (1) | PL2838888T3 (2) |
| PT (1) | PT2838888T (2) |
| SI (1) | SI2838888T1 (2) |
| WO (1) | WO2013124413A1 (2) |
| ZA (1) | ZA201406225B (2) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6073377B2 (ja) | 2012-02-24 | 2017-02-01 | エーエスディー セラピューティクス パートナーズ エルエルシーＡｓｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｐａｒｔｎｅｒｓ Ｌｌｃ | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
| PL2970890T3 (pl) | 2013-03-14 | 2020-11-16 | The Brigham And Women's Hospital, Inc. | Kompozycje i sposoby ekspansji i hodowli nabłonkowych komórek macierzystych |
| MX388409B (es) * | 2014-06-12 | 2025-03-19 | Cedars Sinai Medical Center | Composiciones y metodos para tratar canceres. |
| EP3189134A1 (en) | 2014-09-03 | 2017-07-12 | The Brigham and Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| US11021687B2 (en) | 2016-01-08 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| EP3562827A1 (en) | 2016-12-30 | 2019-11-06 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| JP2021533788A (ja) | 2018-08-17 | 2021-12-09 | フリークエンシー セラピューティクス インコーポレイテッド | Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法 |
| CN113168150B (zh) * | 2018-10-16 | 2024-05-10 | 意大利技术联盟有限责任公司 | 具有被处理幅材的评估系统的卷绕机和方法 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| CA3207901A1 (en) * | 2021-02-11 | 2022-08-18 | Jason Roberts | Compositions and methods for treating arrhythmogenic cardiomyopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| AU783615B2 (en) * | 2000-05-11 | 2005-11-17 | Consejo Superior De Investigaciones Cientificas | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 |
| EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| KR100837785B1 (ko) * | 2007-01-17 | 2008-06-13 | 한국화학연구원 | 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 |
| JP6073377B2 (ja) | 2012-02-24 | 2017-02-01 | エーエスディー セラピューティクス パートナーズ エルエルシーＡｓｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｐａｒｔｎｅｒｓ Ｌｌｃ | Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン |
-
2013
- 2013-02-22 JP JP2014558118A patent/JP6073377B2/ja active Active
- 2013-02-22 DK DK13705492.0T patent/DK2838888T3/en active
- 2013-02-22 WO PCT/EP2013/053554 patent/WO2013124413A1/en not_active Ceased
- 2013-02-22 SI SI201330704T patent/SI2838888T1/sl unknown
- 2013-02-22 CA CA2865351A patent/CA2865351C/en active Active
- 2013-02-22 LT LTEP13705492.0T patent/LT2838888T/lt unknown
- 2013-02-22 HU HUE13705492A patent/HUE035089T2/hu unknown
- 2013-02-22 PL PL13705492T patent/PL2838888T3/pl unknown
- 2013-02-22 ES ES13705492.0T patent/ES2632428T3/es active Active
- 2013-02-22 PT PT137054920T patent/PT2838888T/pt unknown
- 2013-02-22 EP EP13705492.0A patent/EP2838888B1/en active Active
- 2013-02-22 IN IN7885DEN2014 patent/IN2014DN07885A/en unknown
- 2013-02-22 AU AU2013224041A patent/AU2013224041B2/en active Active
- 2013-02-22 HR HRP20170964TT patent/HRP20170964T1/hr unknown
- 2013-02-22 NZ NZ630615A patent/NZ630615A/en unknown
- 2013-02-22 US US14/380,623 patent/US9371299B2/en active Active
-
2014
- 2014-08-25 ZA ZA2014/06225A patent/ZA201406225B/en unknown
-
2016
- 2016-05-16 US US15/155,437 patent/US9469618B2/en active Active
-
2017
- 2017-01-04 JP JP2017000211A patent/JP6518270B2/ja active Active
- 2017-07-12 CY CY20171100737T patent/CY1119231T1/el unknown
- 2017-10-20 AU AU2017248556A patent/AU2017248556B2/en active Active